Eterna Therapeutics Inc. (ERNA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update
Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Currently, 3.3% of the company's shares are sold short. Based on an
Eterna Therapeutics Inc. (ERNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eterna Therapeutics Inc. ever had a stock split?
Eterna Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sanjeev Luther CEO | NASDAQ (CM) Exchange | 114082407 CUSIP |
| US Country | 6 Employees | - Last Dividend | 4 May 2026 Last Split | 19 Oct 1992 IPO Date |
Overview
Eterna Therapeutics Inc. is an innovative life science company, established in 2018 and headquartered in Cambridge, Massachusetts. Specializing in mRNA cell engineering technologies, Eterna is at the forefront of developing solutions for cell reprogramming and gene editing. Through a strategic license agreement with Factor Bioscience Limited, Eterna Therapeutics leverages cutting-edge research to pave the way for advancements in genetic therapies and biotechnology.
Products and Services
- mRNA Cell Reprogramming and Gene Editing
- NoveSlice and UltraSlice Gene-Editing Proteins
- ToRNAdo mRNA Delivery System
This core technology offered by Eterna Therapeutics revolutionizes how scientists approach genetic manipulation, enabling precise alterations in the genetic makeup of cells. It is foundational for developing treatments for genetic disorders and advancing regenerative medicine.
Eterna's proprietary gene-editing proteins, NoveSlice and UltraSlice, represent groundbreaking tools in the field of genome editing. These proteins allow for highly efficient and targeted modifications of DNA, providing a robust platform for therapeutic development and biomedical research.
The ToRNAdo mRNA Delivery System is a state-of-the-art technology developed by Eterna for the efficient delivery of mRNA therapeutics. This system ensures that mRNA can be delivered to target cells with high efficacy, a crucial aspect for the success of mRNA-based therapies.
